medigraphic.com
ISSN 2395-8979 (Electronic)
CuidArte ”El Arte del Cuidado”

2024, Number 25

<< Back Next >>

CuidArte 2024; 13 (25)

Chronic kidney disease in Mexico: challenges and proposals

Reynaga OL, Olivares DEM

Language: Spanish
References: 85
Page:
PDF size: 333.69 Kb.


ABSTRACT

Introduction. Chronic kidney disease (CKD) is one of the main causes of morbidity and mortality in Mexico. Its impact on affected individuals and their families is well understood. In order to reflect on the challenges posed by the current reality, a comprehensive analysis of the situation in Mexico was carried out, focusing on unmet needs and contrasting with internationally reported data to conclude with proposals based on evidence. Body. People with CKD face a convoluted, uninformed, and limited process, which is the result of a fragmented, insufficient, and costly healthcare system. In the authors´; opinion, the main challenges are timely access to preventive and substitutive treatment (including kidney transplantation), truly informed consent, the option of conservative treatment, education as the foundation for patient and family care, quality of life as a determining factor, and consideration of costs. The proposals mainly focus on changes in public health policies to meet the needs of care. Conclusion. CKD presents a public health problem in Mexico that requires immediate—and no less complex—action. The authors propose a radical change toward a model of care which is centered on the person and involves healthcare professionals as well as public decision-makers and policymakers. This model aims to be more cost- efficient and, most importantly, to improve outcomes in quality of life for people with CKD.


REFERENCES

  1. Treviño-Becerra A. Insuficiencia renal crónica: enfermedad emergente, catastrófica y por ello prioritaria. CirCir [Internet] 2004 [consultado 15 diciembre 2020]; 72(1):3–4. Disponible en: https://web.archive.org/web/20170919023836id_/http://www.medigraphic.com:80/pdfs/circir/cc-2004/cc041a.pdf

  2. Tobar F. La Enfermedad como Catástrofe. Salud [Internet] 2010 [consultado 15 diciembre 2020]; 5(22):60–

  3. Disponible en: https://www3.paho.org/hq/dmdocuments/2010/enfermedadcomocatastrofe.pdf3. Bello AK, Levin A, Lunney M, Osman MA, Ye F, Ashuntantang G, et al. Global Kidney Health Atlas: A reportby the International Society of Nephrology on the Global Burden of End-stage Kidney Disease and Capacityfor Kidney Replacement Therapy and Conservative Care across World Countries and Regions [Monografíaen Internet]. Brussels, Belgium; 2019. [Consultado 8 septiembre 2020]. Disponible en: https://www.theisn.org/wp-content/uploads/2021/05/GKHAtlas_2019_WebFIle-1.pdf

  4. Teerawattananon Y, Tungsanga K, Hakiba S, Dabak S. Dispelling the myths of providing dialysis in low- andmiddle-income countries. Nat Rev Nephrol [Internet] 2021 [citado 12 enero 2021];17(1):11–2. doi: https://doi.org/10.1038/s41581-020-00346-7

  5. Canney M, Birks P, Levin A. Epidemiology of Chronic Kidney Disease—Scope of the Problem. En: ChronicRenal Disease [Internet]. 2da ed. [Consultado 15 diciembre 2020] Academic Press; 2020. p. 75–89. doi:http://dx.doi.org/10.1016/B978-0-12-815876-0.00006-1

  6. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden ofchronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. TheLancet [Internet] 2020 [consultado 8 septiembre 2020];395(10225):709–33. doi: https://doi.org/10.1016/S0140-6736(20)30045-3

  7. Cockwell P, Fisher LA. The global burden of chronic kidney disease. The Lancet [Internet] 2020 [consultado

  8. 8 septiembre 2020]; 395(10225):662–4. https://doi.org/10.1016/S0140-6736(19)32977-08. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice M, Okpechi I, et al. Worldwide access to treatment for endstagekidney disease: a systematic review. The Lancet [Internet] 2015 [consultado 27 abril 2021];385. doi:https://doi.org/10.1016/S0140-6736(14)61601-9

  9. Osman MA, Alrukhaimi M, Ashuntantang GE, Bellorin-Font E, Gharbi MB, Braam B, et al. Global nephrologyworkforce: gaps and opportunities toward a sustainable kidney care system. Kidney Int Suppl (2011)[Internet] 2018 [consultado 6 octubre 2020]; 8:52–63. doi: https://doi.org/10.1016/j.kisu.2017.10.009

  10. Rosa-Diez G, Gonzalez-Bedat M, Ferreiro A, García-García G, Fernandez-Cean J, Douthat W. Burden ofend-stage renal disease (ESRD) in Latin America. Clin Nephrol [Internet] 2016 [consultado 11 febrero2023];86(July):29–33. doi: 10.5414/CNP86S105

  11. Obrador GT, de Arrigunaga S, Cuadra M, Villa AR. Mismatch Between Kidney Disease Burden and NephrologyWorkforce in Mexico. Kidney Int Rep [Internet] 2020 [citado 8 septiembre 2020]; 5:973–6. doi: https://doi.org/10.1016/j.ekir.2020.04.028

  12. Agudelo-Botero M, Cecilia González-Robledo M, Reyes-Morales H, Giraldo-Rodríguez L, Rojas-Russell M,Mino-León D, et al. Health care trajectories and barriers to treatment for patients with end-stage renaldisease without health insurance in Mexico: a mixed methods approach. Int J Equity Health [Internet] 2020[consultado 8 septiembre 2020];19(1). doi: https://doi.org/10.1186/s12939-020-01205-4

  13. Agudelo-Botero M, Valdez-Ortiz R, Giraldo-Rodríguez L, González-Robledo MC, Mino-León D, Rosales-Herrera MF, et al. Overview of the burden of chronic kidney disease in Mexico: Secondary data analysisbased on the Global Burden of Disease Study 2017. BMJ Open [Internet] 2020 [consultado 8 septiembre2020];10(3):35285. doi: http://dx.doi.org/10.1136/bmjopen-2019-035285

  14. Méndez-Durán A. Evolución del tratamiento sustitutivo de la función renal en México en los últimos 10años. Nefrología [Internet] 2021 [consultado 12 julio 2021];41(1):82–3. doi: https://doi.org/10.1016/j.nefro.2020.02.004

  15. Garcia-Garcia G, Chavez-Iñiguez JS. The Tragedy of Having ESRD in Mexico. Kidney Int Rep [Internet] 2018[consultado 8 septiembre 2020];3(5):1027–9. doi: https://doi.org/10.1016/j.ekir.2018.07.018

  16. Valdez-Ortiz R, Navarro-Reynoso F, Olvera-Soto MG, Martin-Alemañy G, Rodríguez-Matías A, Hernández-Arciniega CR, et al. Mortality in Patients With Chronic Renal Disease Without Health Insurance in Mexico:Opportunities for a National Renal Health Policy. Kidney Int Rep [Internet] 2018 [consultado 8 septiembre2020];3(5):1171–82. doi: https://doi.org/10.1016/j.ekir.2018.06.004

  17. Garcia-Garcia G, Tonelli M, Ibarra-Hernandez M, Chavez-Iñiguez JS, Oseguera-Vizcaino MaC. Access tokidney transplantation in Mexico, 2007–2019: a call to end disparities in transplant care. BMC Nephrol[Internet] 2021 [citado 12 febrero 2023];22(1):99. doi: https://doi.org/10.1186/s12882-021-02294-1

  18. Obrador GT, Rubilar X, Agazzi E, Estefan J. The challenge of providing renal replacement therapy indeveloping countries: The Latin American perspective. American Journal of Kidney Diseases [Internet] 2016[consultado 12 enero 2021];67(3):499–506. doi: http://dx.doi.org/10.1053/j.ajkd.2015.08.033

  19. Pecoits-Filho R, Sola L, Correa-Rotter R, Claure-Del Granado R, Douthat WG, Bellorin-Font E. Kidney diseasein Latin America: current status, challenges, and the role of the ISN in the development of nephrology inthe region. Kidney Int [Internet] 2018 [cconsultado 8 septiembre 2020];94(6):1069–72. doi: https://doi.org/10.1016/j.kint.2018.07.026

  20. Cortés-Sanabria, L., Álvarez-Santana, G., Orozco-González, C.N., Soto-Molina, H., Martínez-Ramírez, H.R.and Cueto-Manzano, A.M. Impacto económico de la enfermedad renal crónica: Perspectiva del InstitutoMexicano del Seguro Social. Rev Med Inst Mex Seguro Soc [Internet] 2017 [consultado 20 agosto 2023];55(2), pp.124-132. Disponible en: https://www.redalyc.org/articulo.oa?id=457755436004

  21. Méndez-Durán A, Humberto Ignorosa-Luna M, Pérez-Aguilar G, Rivera-Rodríguez FJ, de Jesús González-Izquierdo J, Dávila-Torres J. Estado actual de las terapias sustitutivas de la función renal en el InstitutoMexicano del Seguro Social. Rev Med Inst Mex Seguro Soc [Internet] 2016 [consultado 11 febrero 2023];54. Disponible en: https://www.medigraphic.com/pdfs/imss/im-2016/im165g.pdf

  22. Sánchez-Ramírez O, Olivares-Durán EM, Argüero-Sánchez R. Trasplante renal. Análisis de productividadpanamericana e ibérica en 2019 con una perspectiva mexicana y de la enfermedad renal crónica. GacMed Mex [Internet] 2021 [consultado 11 febrero 2023];157(6):600–7. doi: https://doi.org/10.24875/GMM.M21000620

  23. European Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM). InternationalFigures on donation and transplantation 2017 [Internet]. Vol. 23, Newsletter Transplant. Strasbourg; 2018.[Consultado 21 febrero 2022]. Disponible en: https://www.edqm.eu/en/newsletter-transplant

  24. Dodds, A. Guidelines for the supportive care of patients with End Stage Renal Disease on the ConservativeManagement Pathway. National Service Framework for Renal Services. National Health Services.United Kingdom. 2017. Disponible en: https://www.thinkkidneys.nhs.uk/kquip/wp-content/uploads/sites/5/2017/12/Guidelines-For-the-Conservative.pdf

  25. Robinson B, Zhang J, Morgenstern H, Bradbury BD, Ng LJ, Mccullough K, et al. World-wide, mortalityis a high risk soon after initiation of hemodialysis. Kidney Int [Internet] 2014 [consultado 12 febrero2023];85(1):158–65. doi: https://doi.org/10.1038/ki.2013.252

  26. van Loon IN, Goto NA, Boereboom FTJ, Verhaar MC, Bots ML, Hamaker ME. Quality of life after the initiationof dialysis or maximal conservative management in elderly patients: A longitudinal analysis of the Geriatricassessment in OLder patients starting Dialysis (GOLD) study. BMC Nephrol [Internet] 2019 [consultado 12febrero 2023];20(1):1–8. doi: https://doi.org/10.1186/s12882-019-1268-3

  27. Instituto Mexicano del Seguro Social. Prevención, Diagnóstico y Tratamiento de la Enfermedad RenalCrónica. Guía de Evidencias y Recomendaciones: Guía de Práctica Clínica. Catálogo maestro CENETEC[Internet] 2019 [consultado 12 febrero 2023]; Disponible en: http://www.cenetec-difusion.com/CMGPC/GPC-IMSS-335-19/ER.pdf

  28. Reyes-Acevedo R, Obrador GT, Alberú-Gómez J, Gracida-Juárez C, André Madrigal J, Aburto-Morales S. CurrentState and Challenges for Organ Donation and Transplantation in Mexico. Transplantation [Internet] 2019[consultado 8 septiembre 2020];103(4):648–50. doi: https://doi.org/10.1097/TP.0000000000002474

  29. Luyckx VA, Miljeteig I, Ejigu AM, Moosa MR. Ethical Challenges in the Provision of Dialysis in Resource-Constrained Environments. Semin Nephrol [Internet] 2017[consultado 9 febrero 2021];37(3):273–86. doi:http://dx.doi.org/10.1016/j.semnephrol.2017.02.007

  30. Sinclair A, Cimon K, Loncar M, Sood M, Komenda P, Severn M, et al. Dialysis Modalities for the Treatmentof End-Stage Kidney Disease: A Health Technology Assessment. [Monografía en Internet]. Ottawa; 2017[Consultado 9 febrero 2021]. CADTH Optimal Use Report; vol.6, núm.2b. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30325617/

  31. Cassidy BP, Getchell LE, Harwood L, Hemmett J, Moist LM. Barriers to Education and Shared Decision Makingin the Chronic Kidney Disease Population: A Narrative Review. Can J Kidney Health Dis [Internet] 2018[consultado 12 febrero 2023]; 5:205435811880332. doi: https://doi.org/10.1177/2054358118803322

  32. Easom AM, Shukla AM, Rotaru D, Ounpraseuth S, Shah S v, Arthur JM, et al. Home run—results of a chronickidney disease Telemedicine Patient Education Study. Clin Kidney J [Internet] 2020 [consultado 12 febrero2023];13(5):867–72. doi: https://doi.org/10.1093/ckj/sfz096

  33. Malkina A, Tuot DS. Role of telehealth in renal replacement therapy education. Semin Dial [Internet] 2018[consultado 12 febrero 2023];31(2):129–34. doi: https://doi.org/10.1111/sdi.12663

  34. Shukla AM, Hinkamp C, Segal E, Ozrazgat Baslanti T, Martinez T, Thomas M, et al. What do the USadvanced kidney disease patients want? Comprehensive pre-ESRD Patient Education (CPE) and choice ofdialysis modality. PLoS One [Internet] 2019 [consultado 12 febrero 2023];14(4): e0215091. doi: https://doi.org/10.1371/journal.pone.0215091

  35. Arad M, Goli R, Parizad N, Vahabzadeh D, Baghaei R. Do the patient education program and nurse-ledtelephone follow-up improve treatment adherence in hemodialysis patients? A randomized controlledtrial. BMC Nephrol [Internet] 2021 [consultado 12 febrero 2023];22(1):119. doi: https://doi.org/10.1186/s12882-021-02319-9

  36. febrero 2023];29(15–16):2834–48. doi: https://doi.org/10.1111/jocn.15301

  37. Alghamdi AA, Almotairy KA, Aljoaid RM, al Turkistani NA, Domyati RW, Morsy Abdelrahman MM, et al.The Impact of a Pre-Dialysis Educational Program on the Mode of Renal Replacement Therapy in a SaudiHospital: A Retrospective Cohort Study. Cureus [Internet] 2020 [consultado 12 febrero 2023];12(12). doi:https://doi.org/10.7759/cureus.11981

  38. Fishbane S, Agoritsas S, Bellucci A, Halinski C, Shah HH, Sakhiya V, et al. Augmented Nurse CareManagement in CKD Stages 4 to 5: A Randomized Trial. Am J Kidney Dis [Internet] 2017 [consultado 21julio 2021];70(4):498–505. doi: http://dx.doi.org/10.1053/j.ajkd.2017.02.366

  39. st. Clair Russell J, Boulware LE. End-stage renal disease treatment options education: What matters mostto patients and families. Semin Dial [Internet] 2018 [consultado 12 febrero 2023];31(2):122–8. doi: http://dx.doi.org/10.1111/sdi.12665

  40. Farley H. Promoting self-efficacy in patients with chronic disease beyond traditional education: A literaturereview. Nurs Open [Internet] 2020 [consultado 12 febrero 2023];7(1):30–41. doi: https://doi.org/10.1002/nop2.382

  41. Kaiser P, Pipitone O, Franklin A, Jackson DR, Moore EA, Dubuque CR, et al. A Virtual Multidisciplinary CareProgram for Management of Advanced Chronic Kidney Disease: Matched Cohort Study. J Med Internet Res[Internet] 2020 [consultado 21 julio 2021];22(2):e17194. doi: https://doi.org/10.2196/17194

  42. Shukla AM, Bozorgmehri S, Ruchi R, Mohandas R, Hale-Gallardo JL, Ozrazgat-Baslanti T, et al. Utilizationof CMS pre-ESRD Kidney Disease Education services and its associations with the home dialysistherapies. Perit Dial Int [Internet] 2021 [consultado 12 febrero 2023];41(5):453–62. doi: https://doi.org/10.1177/0896860820975586

  43. Schanz M, Ketteler M, Heck M, Dippon J, Alscher MD, Kimmel M. Impact of an in-hospital patient educationprogram on choice of renal replacement modality in unplanned dialysis initiation. Kidney Blood Press Res[Internet] 2018 [consultado 12 febrero 2023];42(5):865–76. doi: https://doi.org/10.1159/000484531

  44. Elías-Viramontes A de C, Casique-Casique, Leticia Rodríguez-Loreto JE. La persona con enfermedad renalcrónica: una revisión sistemática de las intervenciones de salud. Enfermeria Nefrológica [Internet] 2020[consultado 30 junio 2021];23(4):333–44. https://doi.org/10.37551/S2254-28842020034

  45. Foundation NK. 2006 Updates Clinical Practice Guidelines and Recommendations. Hemodialysis AdequacyPeritoneal Dialysis Adequacy Vascular Access A Curriculum for CKD Risk Reduction and Care Kidney LearningSystem (KLS)TM [Monografía en Internet]. New York, NY; 2006. [Consultado 12 enero 2021]. Disponible en:https://www.kidney.org/sites/default/files/docs/12-50-0210_jag_dcp_guidelines-hd_oct06_sectiona_ofc.pdf

  46. United Healthcare. Kidney Disease Education – Medicare Advantage Coverage Summary [Monografíaen Internet]. EUA. 2010. [Consultado 29 de septiembre 2023]. Disponible en: https://www.cms.gov/regulations-and-guidance/guidance/transmittals/downloads/r1876cp.pdf

  47. Centers of Medicare & Medicaid Services. Usted Puede Vivir: Su Guía para Vivir con Insuficiencia Renal[Monografía en Internet]. Baltimore, Maryland, USA: Department of Health & Human Services; 2007. p. 40.[Consultado 23 marzo 2023]. Disponible en: https://silo.tips/download/usted-puede-vivir-su-guia-paravivir-con-insuficiencia-renal

  48. Kidney Research UK. Diálisis: tomar las decisiones que mejor se adapten a usted [Monografía en Internet].Kidney Research UK, editor. Sociedad Española de Nefrología; p. 1–56. 2015. [Consultado 23 marzo 2021].Disponible en: https://www.med-decs.org/images/keuzehulp/dialysis-spanish.pdf

  49. Fundación Mexicana del Riñon AC. Pronto [Monografía en Internet]. México. p. 1–5. 2019. [Consultado 12agosto 2021]. Disponible en https://fundacionrenal.org/pronto/

  50. Aqtam I, Ayed A, Zaben K. Quality of Life: Concept Analysis. Saudi J Nurs Health Care [Internet] 2023[consultado 23 marzo 2023];6(1):10-5. doi: https://doi.org/10.36348/sjnhc.2023.v06i01.003

  51. Centers for Disease Control and Prevention. (2019). HRQOL Concepts. [Sitio en Internet]. [Consultado 23marzo 2023]. Disponible en https://www.cdc.gov/hrqol/concept.htm

  52. de Brito DCS, Machado EL, Reis IA, Moreira DP, Nébias THM, Cherchiglia ML. Modality transition on renalreplacement therapy and quality of life of patients: a 10-year follow-up cohort study. Quality of Life Research[Internet] 2019 [consultado 8 septiembre 2021];28(6):1485–95. doi: http://dx.doi.org/10.1007/s11136-019-02113-z

  53. Reynaga-Ornelas L. Impact of sleep and dialysis mode on quality of life in a Mexican population. SouthwestJ Pulm Crit Care [Internet] 2019 [consultado 8 junio 2021];18(5):122–34. doi: https://doi.org/10.13175/swjpcc017-19

  54. Yang F, Yang Z, Cheng L, Tong J, Wang P. Quality of Life and Depression in Patients with End-stage RenalDisease: A Comparison of Renal Replacement Therapy Modalities. Res Sq [Internet] 2021 [consultado 15junio 2021];1–16. doi: https://doi.org/10.21203/rs.3.rs-189187/v1

  55. Alhaji MM, Yee HK, Alam S, Hossain M, Khan A, Tan J. Health-Related Quality of End-Stage RenalDisease Patients Undergoing Renal Replacement Therapy. KJMS [Internet]. 2018 [consultado 12 febrero2023];11(2):1–5. Disponible en: https://kjms.com.pk/old/sites/default/files/KJMS-1_4.pdf

  56. Treated With Different Renal Replacement Therapies. Therapeutic Apheresis and Dialysis [Internet] 2021[consultado 12 febrero 2022];26(1):115–21. doi: https://doi.org/10.1111/1744-9987.13692

  57. dialysis patients with renal insufficiency. Patient Prefer Adherence [Internet] 2018 [consultado 15 junio2021];12:577–83. doi: https://doi.org/10.2147/PPA.S156356

  58. Iga DP. Quality of Life of Children with Chronic Kidney Disease Undergoing Renal Replacement Therapy.Journal keperawatan Cikini [Internet] 2018 [consultado 12 febrero 2023];04(04):19–23. doi: https://doi.org/10.4172/2472-1220.1000173

  59. stage renal disease patients undergoing hemodialysis and peritoneal dialysis in a Moroccan city. Seminarsin Dialysis [Internet] 2022 [consultado 23 marzo 2023]; 35(01):50-57. doi: https://doi.org/10.1111/sdi.13034

  60. Chuasuwan A, Pooripussarakul S, Thakkinstian A, Ingsathit A, Pattanaprateep O. Comparisons of qualityof life between patients underwent peritoneal dialysis and hemodialysis: a systematic review and metaanalysis.Health Qual Life Outcomes [Internet] 2020 [consultado 8 julio 2021]; 12:191. doi: https://doi.org/10.1186/s12955-020-01449-2

  61. Hernández-Cantú EI, Maldonado-Saucedo M. Calidad de vida en pacientes nefrópatas con distintostratamientos en un hospital de segundo nivel de atención en Nuevo León. Enfermeria Global [Internet] 2019[consultado 14 julio 2021];53:255–67. doi: http://dx.doi.org/10.6018/eglobal.18.1.322491

  62. Martínez-Gutiérrez F, Roy-García IA, Torres-Rodríguez JL. Terapia sustitutiva y su impacto en calidad devida de pacientes con enfermedad renal crónica terminal. Atención Familiar [Internet] 2019 [consultado 12febrero 2023];27(1):22. doi: https://doi.org/10.22201/facmed.14058871p.2020.1.72277

  63. Queeley GL, Campbell ES. Comparing treatment modalities for end-stage renal disease: A meta-analysis.Am Health Drug Benefits [Internet] 2018 [consultado 1 de junio de 2021];11(3):118–27. doi: https://doi.org/10.1016/j.jval.2014.03.1690

  64. Ramos-Alcocer JR, Salas-Nolasco OI, Villegas-Domínguez JE, Serrano-Vázquez CW, Dehesa-López E,Márquez-Celedonio FG. Calidad de vida y factores asociados en enfermedad renal crónica con terapia desustitución. Archivos en Medicina Familiar [Internet] 2021 [consultado 1 junio 2021;23(2):75–83. Disponibleen: https://www.medigraphic.com/pdfs/medfam/amf-2021/amf212d.pdf

  65. Yao X, Lei W, Shi N, Lin W, Du X, Zhang P, et al. Impact of initial dialysis modality on the survival of patientswith ESRD in eastern China: A propensity-matched study. BMC Nephrol [Internet] 2020 [consultado 30 junio2021];21(1):1–10. doi: https://doi.org/10.1186/s12882-020-01909-3

  66. Karkar A, Wilkie M. Peritoneal dialysis in the modern era. Perit Dial Int [Internet] 2022 [consultado 15 junio2021]:08968608221114211. doi: https://doi.org/10.1177/08968608221114211

  67. Cortés-Sanabria L, Álvarez-Santana G, Orozco-González CN, Soto-Molina H, Martínez-Ramírez HR, Cueto-Manzano AM. Impacto económico de la enfermedad renal crónica: Perspectiva del Instituto Mexicano delSeguro Social. Rev Med Inst Mex Seguro Soc [Internet] 2017 [consultado 12 febrero 2023];55(Suppl 2):S124-32. Disponible en: https://www.redalyc.org/articulo.oa?id=457755436004

  68. Mohnen SM, van Oosten MJM, Los J, Leegte MJH, Jager KJ, Hemmelder MH, et al. Healthcare costs ofpatients on different renal replacement modalities – Analysis of Dutch health insurance claims data. PLoSOne [Internet] 2019 [consultado 15 junio 2021];14(8):e0220800. doi: https://doi.org/10.1371/journal.pone.0220800.g001

  69. Salas-Zapata L, Palacio-Mejía LS, Aracena-Genao B, Hernández-Ávila JE, Nieto-López ES. Costos directos delas hospitalizaciones por diabetes mellitus en el Instituto Mexicano del Seguro Social. Gac Sanit [Internet]2018 [consultado 12 febrero 2023];32(3):209–15. doi: https://doi.org/10.1016/j.gaceta.2016.06.015

  70. Afiatin, Khoe LC, Kristin E, Masytoh LS, Herlinawaty E, Werayingyong P, et al. Economic evaluation of policyoptions for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia.PLoS One [Internet] 2017 [Consultado 12 febrero 2023];12(5):1–10. doi: https://doi.org/10.1371/journal.pone.0177436

  71. A narrative review. Seminars in dialysis [Internet] 2019 [consultado 24 marzo 2023];32(5):452-462. doi:https://doi-org.ezproxy1.lib.asu.edu/10.1111/sdi.12770

  72. Hong, Z., Zhuang, Y., Lu, J. et al. Economic evaluation of three dialysis methods in patients with end-stagerenal disease in China. Int Urol Nephrol [Internet] 2022 [consultado 24 marzo 2023](1-8). doi: https://doi.org/10.1007/s11255-022-03402-2

  73. Méndez-Durán A. Comportamiento de la referencia a trasplante renal en el Instituto Mexicano delSeguro Social. Rev Mex Tras [Internet] 2020 [consultado 12 enero 2021];9(2):51–5. doi: https://doi.org/10.35366/95707

  74. Piccoli G, Breuer C, Cabiddu G, Testa A, Jadeau C, Brunori G. Where Are You Going, Nephrology?Considerations on Models of Care in an Evolving Discipline. J Clin Med [Internet] 2018 [consultado 12febrero 2023];7(8):199. doi: https://doi.org/10.3390/jcm7080199

  75. Tamayo-Orozco J, Lastiri-Quirós S. La enfermedad renal crónica en México [Internet]. 2016a ed. AcademiaNacional de Medicina de México, editor. Enfermedad renal crónica en México: una política nacional todavíapendiente. México: Intersistemas S.A. de C.V., 2016:82. [Consultado 12 febrero 2023]. Disponible en:https://www.anmm.org.mx/publicaciones/ultimas_publicaciones/ENF-RENAL.pdf

  76. Wokoma F, Emem-Chioma P, David-West M. Community-Focused Primary Prevention of Risk Factors ofChronic Kidney Diseases (CKD): An Unmet Need in Reducing the Burden of ESRD in Low and Middle-IncomeCountries (LIMC). Tropical Journal of Nephrology [Internet] 2019 [consultado 19 agosto 2020];14(2):67–88.Disponible en: https://tjn-online.com/index.php/tjn/article/view/182

  77. Garcia-Garcia G, Martinez-Castellanos Y, Renoirte-Lopez K, Barajas-Murguia A, de la Torre-Campos L, Becerra-Muñoz LE, et al. Multidisciplinary care for poor patients with chronic kidney disease in Mexico. KidneyInt Suppl (2011) [Internet] 2013 [consultado 14 julio 2021];3(2):178–83. doi: https://doi.org/10.1038/KISUP.2013.9

  78. Vasquez-Jimenez E, Madero M. Global Perspectives Global Dialysis Perspective: Mexico. Kidney360 [Internet]2020 [consultado 12 enero 2021]; 1:534–7. doi: https://doi.org/10.34067/KID.0000912020

  79. Thaweethamcharoen T, Sritippayawan S, Noparatayaporn P, Aiyasanon N. Cost-Utility Analysis of ContinuousAmbulatory Peritoneal Dialysis and Automated Peritoneal Dialysis for Thai Patients with End-Stage RenalDisease. Value Health Reg Issues [Internet] 2020 [consultado 19 julio 2021]; 21:181–7. doi: https://doi.org/10.1016/J.VHRI.2019.10.004

  80. Niang A, Iyengar A, Luyckx VA. Hemodialysis versus peritoneal dialysis in resource-limited settings. CurrOpin Nephrol Hypertens [Internet] 2018 [consultado 15 febrero 2023];27(6):463–71. doi: https://doi.org/10.1097/MNH.0000000000000455

  81. Gilardino RE, González-Pier E, Brabata C. End-Stage Renal Disease Models in the Americas: OptimizingResources to Achieve Better Health Outcomes. Value Health Reg Issues [Internet] 2018 [consultado 12enero 2021]; 17:115–8. doi: https://doi.org/10.1016/j.vhri.2018.04.001

  82. Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, et al. Summary of the Kidney Disease: ImprovingGlobal Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates forKidney Transplantation. Transplantation [Internet] 2020 [consultado 12 enero 2021];104(4):708–13. doi:https://doi.org/10.1097/TP.0000000000003137

  83. O’Connell PJ, Brown M, Mao Chan T, Claure-Del Granado R, Davies SJ, Eiam-Ong S, et al. The role ofkidney transplantation as a component of integrated care for chronic kidney disease. Kidney Int Suppl(2011) [Internet] 2020 [consultado 30 septiembre 2020];10: e78–85. doi: https://doi.org/10.1016/j.kisu.2019.11.006

  84. Campbell-Montalvo R, Jia H, Shukla AM. Supporting Shared Decision-Making and Home Dialysis in End-StageKidney Disease. International Journal of Nephrology and Renovascular Disease [Internet] 2022 [consultado8 septiembre 2021]; 15:229-37. doi: https://doi.org/10.2147/IJNRD.S375347

  85. American Association of Kidney Patients [Sitio en Internet].. Decade of the Kidney. Center for patientengagement and advocacy. 2021. p. 1–6. [Consultado 30 septiembre 2020]. Disponible en: https://aakp.org/center-for-patient-engagement-and-advocacy/decade-of-the-kidney/




2020     |     www.medigraphic.com